RE:RE:RE:BMS enters into a USD$ 2 Billion with startup companyUnfortunately the mining and oil/gas purists here would prefer to avoid the usefullness of comparables which serve to illustrate that Big Pharma is confronting a looming patent cliff and is will to pay $Billions for startup companies. Imagine what these same Big Pharma companies are willing to pay for the acquisition of mid-late stage biotech companies with "bolt-on" assets.
PwC has projected that Big Pharma's "sweet- spot" for "bolt-on" acquisitions is currently around USD$ 5 Billion to USD$ 15 Billion.